SHORT COMMUNICATION

The risk of developing a *Clostridium difficile* infection from the administration of different classes of antibiotics and their combinations to children in an oncological hospital

Mariya G. Shvydkaya1*, Aleksandr M. Zatevalov1, Dzhamilya T. Dzhandarova2, Sergey D. Mitrokhin3

1 G. N. Gabrichevsky research institute for epidemiology and microbiology, Rospotrebnadzor, Moscow, Russian Federation
2 Diagnostic Clinical Center No. 1, Moscow, Russian Federation
3 City Clinical Hospital No. 67 named after L. A. Vorokhobov, Moscow, Russian Federation

*Corresponding author: Maria Shvydkaya, e-mail: mshvidkaya@mail.ru

Keywords: *Clostridium difficile* infection, pediatric oncology, antibiotics

**DOI:** 10.18527/2500-2236-2020-7-1-54-58

Received October 21, 2020 Accepted November 19, 2020 Published December 24, 2020

**ABSTRACT**

Patients in pediatric oncological hospitals are at risk of developing a *Clostridium difficile* infection. The purpose of this study was to determine the risk of developing a *Clostridium difficile* infection in patients who are treated with antibiotics of different classes and their combinations by way of a retrospective analysis of 122 patient records. It was shown that the administration of antibacterial chemotherapeutic drugs that belong to the classes of nitrofurans (enterofuryl), sulfonamides (biseptol), cephalosporins, and macrolides/azalides significantly increased the risk of developing a *Clostridium difficile* infection in pediatric patients. On the contrary, treatment with antibiotics of different classes, such as linezolid, colistin, and metronidazole, significantly reduced the risk of developing a *Clostridium difficile* infection. The use of penicillins, aminoglycosides, fluoroquinolones, glycopeptides, and carbapenems was not associated with the risk of developing a *Clostridium difficile* infection in pediatric patients. The administration of one or two antimicrobial drugs of different classes increased the risk of developing a *Clostridium difficile* infection while a combination of three different types of antimicrobial drugs lowered the rate of this infection in pediatric patients.

**INTRODUCTION**

One side effect of antibiotics is the development of a multiple drug resistance of opportunistic microflora and the inhibition of the growth of indigenous human microflora. In these circumstances, conditionally pathogenic human microflora can cause serious diseases. Therefore, the predominance of *Clostridium difficile* (*C. difficile*) in the intestinal microbiota can cause both mild disease and serious illnesses, such as pseudomembranous colitis, toxic megacolon, intestinal perforation, and intestinal bleeding [1]. *C. difficile* diarrhea has been the cause of increased morbidity and mortality among hospitalized patients worldwide since 2000 [2, 3]. According to the Centers for Disease Control and Prevention (CDC, USA), in the United States alone, there are more than 400,000 cases of *C. difficile* infection with 29,000 fatalities every year [4]. Infections acquired in hospitals account for about two thirds of this amount. *C. difficile* is an anaerobic spore-forming Gram-positive bacterium of the *Peptostreptococcaceae* family of the *Clostridia* class, which belongs to opportunistic microorganisms present in the colon that develop during dysbiosis [5]. The development of a *C. difficile* infection is associated with the production of cellular toxins A (enterotoxin) and B (cytotoxin). These toxins bind to the surface of intestinal epithelial cells causing their death and lead to local inflammation [6].

A weakened immune status, disruption of the mucous membranes, and reduced conversion of primary bile salts into secondary ones observed in patients with impaired intestinal microflora are the main factors contributing to the disease [7]. Cancer patients who undergo anticancer chemotherapy and treatment with antimicrobial drugs over the course of long-term hospitalization have a high risk of developing a *C. difficile* infection [8-10]. According to Garzotto et al., one of the main factors in the development of a *C. difficile* infection is treatment with antibiotics rather than the type of tumor or anticancer therapy [11]. However, Anand et al. showed that cytotoxic chemotherapeutic agents themselves are capable of causing a *C. difficile* infection in the absence of antibiotics [12].

When treating children with an anticipated long stay in the hospital, it is common practice to supplement the main therapy with several groups of antibiotics [13]. Simultaneous administration of several antibiotics significantly increases the risk of *C. difficile* infection in immunosuppressed patients [14]. The objective of this study was to find the correlation between the administration...
of different classes of antibiotics and their combinations with the incidence of a *Clostridium difficile* infection in children in an oncological hospital.

**MATERIALS AND METHODS**

**Patients and study design**

A retrospective observational study was carried out in an oncological hospital – Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology in Moscow (NSPC PHOI, Russia). A retrospective analysis of 122 patient records of children aged 0 to 18 years was carried out including 48 cases with diagnosed and confirmed *Clostridium difficile* antibiotic-associated enterocolitis. The control group consisted of 74 patients treated in the same hospital at the same time, but without symptoms of intestinal damage and with a negative test for toxins A and B in the feces. At the time of detection of a *Clostridium difficile* infection, the patients were undergoing treatment for the main disease with the addition of the following antimicrobial chemotherapeutic drugs: nitrofurans (enterofuryl), sulfonamides (biseptol), cephalosporins, macrolides/azalides, aminoglycosides, carbapenems, penicillins, fluoroquinolones, lipopeptides (colistin), and oxazolidines (linezolid). The control group received the same drugs.

Confirmation of a *Clostridium difficile* infection in patients was carried out by the detection of toxins A and B in the feces. At the time of detection of a *Clostridium difficile* infection, the patients were undergoing treatment for the main disease with the addition of the following antimicrobial chemotherapeutic drugs: nitrofurans (enterofuryl), sulfonamides (biseptol), cephalosporins, macrolides/azalides, aminoglycosides, carbapenems, penicillins, fluoroquinolones, lipopeptides (colistin), and oxazolidines (linezolid). The control group received the same drugs.

Table 1. The incidence of *Clostridium difficile* infection development depending on the class of ACDs co-administered in the course of treatment of the main disease compared with the control group.

| Antibiotic classes       | Group size | Frequency of *Clostridium difficile* infection occurrence, % | Statistical significance, p |
|--------------------------|------------|---------------------------------------------------------------|------------------------------|
|                          | C. difficile infection | Control group |                                                                     |
| Nitrofurans (enterofuryl)| 4          | 2                | 66.7**                                                                  | 0.0000035                   |
| Sulfonamides (biseptol)  | 27         | 22               | 55.1**                                                                  | 0.0017                      |
| Cephalosporins           | 12         | 10               | 54.5**                                                                  | 0.0020                      |
| Macrolides/azalides      | 6          | 7                | 46.2*                                                                   | 0.022                       |
| Aminoglycosides          | 7          | 10               | 41.2                                                                    | 0.07                        |
| Carbapenems              | 11         | 17               | 39.3                                                                    | 0.12                        |
| Penicillins              | 7          | 17               | 29.2                                                                    | 0.7                         |
| Fluoroquinolones         | 4          | 11               | 26.7                                                                    | 1                           |
| Glycopeptides            | 9          | 26               | 25.7                                                                    | 0.8                         |
| Metronidazole            | 2          | 32               | 5.9**                                                                   | 0.00027                     |
| Polypeptide cyclic (colistin) | 0       | 6                | 0**                                                                     | 0.0000024                   |
| Oxazolidines (linezolid) | 0          | 5                | 0**                                                                     | 0.0000024                   |

*p = p<0.05, ** - p<0.01, *** – p<0.001 indicates the statistically significant increase in the incidence of a *Clostridium difficile* infection in cases with the administration of ACDs.

*** – p<0.001 indicates the statistically significant decrease in the incidence of *Clostridium difficile* infection in cases with the administration of ACDs.

**RESULTS AND DISCUSSION**

Analyzing the results of the therapy of children – patients of the oncological hospital NSPC PHOI, we calculated the frequency of *Clostridium difficile* infections (by toxins A and B detection in the feces) in patients treated with different classes of antibacterial drugs. The results that are shown in Table 1 demonstrate a clear correlation between the use of antibacterial drugs that belong to the classes of nitrofurans, sulfonamides, cephalosporins, and macrolides/azalides and the development of a *Clostridium difficile* infection in patients.

Treatment with enterofuryl (class of nitrofurans, the first group of antibacterials (Table 1)) led to the highest rate (66%) of *Clostridium difficile* infections in patients. Kumar et al. showed the highest frequency of formation of resistant *Clostridium difficile* mutants under the action of nitrofurans [15]. This effect explains the high probability of changing the microbiota composition in patients treated with drugs of the nitrofuran class due to the formation of resistant forms of *Clostridium difficile* that in turn can cause the development of a pathological process.

Treatment with sulfonamides including biseptol – the second group of antibacterial drugs – led to less frequent development (55.1%) of *Clostridium difficile* infections. However, according to Zakharova et al., sulfonamides belong to the group of antimicrobials with a low risk of *Clostridium difficile* infection development. This discrepancy may be due to the wider use of biseptol in children undergoing treatment in an oncological hospital compared with other groups of patients [16].

---

*Volume 7 Number 1 2020 55 mir-journal.org*
The administration of the drugs that belong to the third group – cephalosporin antibiotics – caused the development of *C. difficile* infections in children at a lower rate of 54.5%. This finding is consistent with literature data based on the results of meta-analysis of studies that showed the strongest relationship between the third-generation cephalosporins and *C. difficile* infections acquired in hospitals (hospital-acquired infections, HAIs) [17, 18].

The fourth group of antimicrobials, which includes macrolide/azalide antibiotics, showed a statistically significant correlation with the development of *C. difficile* infections in patients with the lowest rate of 46.2%, which agrees well with the literature data [18]. According to our data, the frequency of the *C. difficile* infection cases after the treatment of patients with carbapenems did not have statistical significance that contradicts the data of Vardakas *et al.* [19]. This could probably be explained by choosing meropenem for our study – the antibacterial agent that has anti-anaerobic activity.

Therefore, we have shown (Table 1) that the use of such antimicrobial chemotherapeutic drugs (ACDs) as nitrofurans, sulfonamides, cephalosporins, and macrolides/azalides in children – patients of an oncological hospital – was associated with the development of *C. difficile* infection. The differences in their effect on patients are possibly related to the patient’s age and the course of treatment of the main disease.

Our data showed that the use of linezolid (group of oxazolidinones) and colistin (a cyclic polypeptide antibiotic) significantly reduced the risk of *C. difficile* infection. This observation is consistent with the literature data on the activity of linezolid *in vitro* against *C. difficile* strains [20] and a low risk of developing a *C. difficile* infection over the course of treatment of patients with colistin [21]. In addition, it should be noted that, in our study, colistin was administered together with anti-anaerobic drugs, which reduces the risk of *C. difficile* infections.

Currently, two antimicrobial drugs registered for the treatment and prevention of *C. difficile* infections are used in Russian pediatric oncological hospitals: vancomycin and metronidazole [22]. It should be noted that, in our study, 2 patients developed a *C. difficile* infection while taking metronidazole and 9 patients – while treating the main disease with vancomycin. That could be explained by the emergence of *C. difficile* strains resistant to these drugs, and it could also be related to the route of administration of the drugs [23]. This issue requires a separate study. Since the problem of the treatment and prevention of *C. difficile* infection in a pediatric oncological clinic remains relevant, it is necessary to search for a new approach to combat this illness.

To assess the risk of the *C. difficile* infection development due to the simultaneous administration of 2 or 3 antibiotics, we compared the results from groups of patients treated with 2 or 3 drugs, group treated with 1 antibiotic as well as a control group that was not treated with antimicrobials. Our results showed (Table 2) that the use of 1 drug or combination of 2 drugs in the treatment significantly increased the risk of *C. difficile* infection development, while the simultaneous administration of 3 antibiotics reduced it. According to Lopes Cançado et al., the amount of antibiotics used during hospitalization played a significant role in the development of *C. difficile* infections [24]. In our study, the reduced risk of *C. difficile* infections in cases where a combination of 3 or more antibiotics were used for the treatment of the patients could be explained by the inclusion of an anti-anaerobic component in this combination.

Therefore, the use of ACDs that belong to the following classes – nitrofurans (enterofuryl), sulfonamides (biseptol), cephalosporins, and macrolides/azalides – significantly increased the risk of the *C. difficile* infection development in children – patients of an oncological hospital. On the contrary, the treatment of pediatric patients with colistin, linezolid, and metronidazole significantly reduced the risk of development of the *C. difficile* infection, whereas the use of penicillins, aminoglycosides, fluoroquinolones, glycopeptides, and carbapenems was not associated with *C. difficile* infection development. The administration of one or two different classes of antimicrobials significantly increased the risk of the *C. difficile* infection development. On the contrary, the simultaneous administration of 3 different classes of antimicrobial drugs reduced the risk of *C. difficile* infection development.

**Table 2.** Frequency of *C. difficile* infection depending on the number of ACDs co-administered in the course of treatment of the main disease

| Development risk of *C. difficile* infection, % | 0 ACD | 1 ACD | 2 ACDs | 3 ACDs and more |
|---------------------------------------------|------|-------|--------|-----------------|
|                                             | 26.6 | 53.3  | 50.0   | 27.2            |
| n=15                                        | n=50 | n=52  | p=0.0029<sup>a</sup> | n=44            |
| p=0.0077<sup>b</sup>                        | p=0.74<sup>b</sup> | p=0.0037<sup>b</sup> | p=0.0036<sup>b</sup> |

a – *p* value corresponding to an increase in the incidence of a *C. difficile* infection with the use of antimicrobial drugs compared with the group in which ACDs were not used.

b – *p* value corresponding to a decrease in the incidence of a *C. difficile* infection with the use of ACDs compared to the group in which 1 ACD was used.

c – *p* value corresponding to a decrease in the incidence of a *C. difficile* infection with the use of ACDs compared with the group in which 2 ACDs were used.
Clostridium difficile infection in children

CONFLICT OF INTEREST
The authors have no commercial or financial interests.

CITATION
Shvydkaya MG, Zatevalov AM, Dzhandarova DT, Mitrokhin SD. The risk of developing a Clostridium difficile infection from the administration of different classes of antibiotics and their combinations to children in an oncological hospital. MIR J. 2020; 7(1), 54-58. doi: 10.18527/2500-2236-2020-7-1-54-58.

REFERENCES
1. Lin HJ, Hung YP, Liu HC, Lee JC, Lee CI, Wu YH, et al. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization. J Microbiol Immunol Infect 2015; 48(2), 183-9. doi: 10.1016/j.jmii.2015.08.003.
2. Czepiel J, Drozdz M, Pituch H, Kuiper EJ, Perucki W, Mielenmonka A, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 2019; 38(7), 1211-21. doi: 10.1007/s10096-019-05539-6.
3. Kelly CP, LaMont JT. Clostridium difficile – more difficult than ever. N Engl J Med 2008; 359(18), 1932-40. doi: 10.1056/NEJMra0707500.
4. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372(9), 825-34. doi: 10.1056/NEJMoa1408913.
5. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330(4), 257-62. doi: 10.1056/NEJM199401273300404.
6. Huelsenbeck J, Dreger SC, Gerhard R, Fritz G, Just I, Genth H. Upregulation of the immediate early gene product RhoB by exoenzyme C3 from Clostridium limosum and toxin B from Clostridium difficile. Biochemistry 2007; 46(16), 4923-31. doi: 10.1021/bi602465z.
7. Taur Y, Pamer EG. Harnessing microbiota to kill a pathogen: Fixing the microbiota to treat Clostridium difficile infections. Nat Med 2014; 20(5), 246-7. doi: 10.1038/nm.3492.
8. Ofori E, Ramai D, Dhaban M, Mustafa F, Casperino J, Reddy M. Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. J Hosp Infect 2018; 99(4), 436-42. doi: 10.1016/j.jhin.2018.01.015.
9. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 355(25), 2442-9. doi: 10.1056/NEJMoa051659.
10. Hautmann MG, Hipp M, Kolbl O. Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol 2011; 6, 89. doi: 10.1186/1748-717X-6-89.
11. Rodriguez Garzotto A, Merida Garcia A, Munoz Unceta N, Galera Lopez MM, Orellana-Miguel MA, Diaz-Garcia CV, et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 2015; 23(6), 1569-77. doi: 10.1007/s00520-014-2506-7.
12. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17(1), 109-13. doi: 10.1093/clinids/17.1.109.
13. Lehnbacher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. Clin Infect Dis 2020; 71(1), 226-36. doi: 10.1093/cid/ciz1082.
14. Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections – an overview of the evidence base and challenges in data synthesis. J Glob Health 2017; 7(1), 010417. doi: 10.7189/jogh.07.010417.
15. Kumar M, Adhikari S, Hurdle JG. Action of nitroheterocyclic drugs against Clostridium difficile. Int J Antimicrob Agents 2014; 44(4), 314-9. doi: 10.1016/j.ijantimicag.2014.05.021.
16. Zakharova IN, Berezhnaya IV, Mumladze EB. Antibiotic-associated diarrhea in children: how to identify, what to do, how to treat? Medical Council 2016; 1(1), 78-89. doi: 10.21518/2079-701X-2016-1-78-89. (In Russian)
17. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69(4), 881-91. doi: 10.1093/jac/dkt477.
18. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, et al. Community-associated...
Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68(9), 1951-61. doi: 10.1093/jac/dkt129.

19. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents 2016; 48(1), 1-10. doi: 10.1016/j.ijantimicag.2016.05.008.

20. Valerio M, Pedromingo M, Munoz P, Alcala L, Marin M, Pelaez T, et al. Potential protective role of linezolid against Clostridium difficile infection. Int J Antimicrob Agents 2012; 39(5), 414-9. doi: 10.1016/j.ijantimicag.2012.01.005.

21. Pereira JB, Farragher TM, Tully MP, Jonathan Cooke J. Association between Clostridium difficile infection and antimicrobial usage in a large group of English hospitals. Br J Clin Pharmacol 2014; 77(5), 896-903. doi: 10.1111/bcp.12255.

22. Shelygin YA, Alyoshkin VA, Sukhina MA, Mironov A Yu, Biko NI, Kozlov RS et al. Clinical guidelines for the diagnosis, treatment and prevention of Clostridium difficile-associated diarrhea (CDI). Clinical guidelines. Moscow: Remedium Volga region; 2019 (In Russian).

23. Banawas SS. Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. Biomed Res Int 2018; 2018, 8414257. doi: 10.1155/2018/8414257.

24. Lopes Cancado GG, Silveira Silva RO, Rupnik M, Nader AP, Starling de Carvalho J, Miana de Mattos Paixao G, et al. Clinical epidemiology of Clostridium difficile infection among hospitalized patients with antibiotic-associated diarrhea in a university hospital of Brazil. Anaerobe 2018; 54, 65-71. doi: 10.1016/j.anaerobe.2018.08.005.